Skip to main content

What the FDA labels say about taking them together

Letermovir and rifampin

Letermovir's FDA label of January 14, 2026 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name letermovir. The letermovir label: “Co-administration of PREVYMIS and rifampin is not recommended due to potential for loss of efficacy of PREVYMIS.”

Check it at the source: the letermovir FDA label on DailyMed (effective January 14, 2026, Merck Sharp & Dohme LLC); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).

What does the letermovir label say about rifampin?

Letermovir label, drug interactions

Concomitant Drug Class and/or Clearance Pathway/Drug Name: rifampin; Effect on Concentration ↓ =decrease, ↑ =increase: ↓ letermovir; Clinical Comments: Co-administration of PREVYMIS and rifampin is not recommended due to potential for loss of efficacy of PREVYMIS.

Source: FDA drug label (PREVYMIS), Merck Sharp & Dohme LLC, effective January 14, 2026 (SPL set 1b49df80-be4f-47e0-a0b7-123f3e69395b), via openFDA; the full label on DailyMed

What does the rifampin label say about letermovir?

Rifampin's label (effective February 11, 2026) does not name letermovir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Letermovir generic labelers
13Rifampin generic labelers
LetermovirRifampin
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$0.679 per capsule 300 mg capsule
Shortage nowNo current entryIn shortage

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?